News | December 19, 2025
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Subscribe To Our Newsletter & Stay Updated
